---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Place in treatment, anticipated use, and care setting"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Place in treatment, anticipated use, and care setting. Topics: International guideline update: development method, Proposed population: adults symptomatic despite H1 antihistamine treatment, Manufacturer positioning: first-line therapy in severe disease or angioedema and second-line advanced therapy, Enrollment of advanced therapy-experienced participants and design for an omalizumab-refractory subpopulation, and 9 further topics. 14 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description/place-in-treatment-anticipated-use-and-care-setting"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Place in treatment, anticipated use, and care setting

<a id="heading-2.2.2.2"></a>

## 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

### Summary

The 2026 international guideline sequences treatment as a standard-dose second-generation H1-antihistamine first line, updosing up to 4-fold second line, then add-on omalizumab (recommended), dupilumab, or remibrutinib (both suggested) for CSU unresponsive to high-dose antihistamines, and off-label ciclosporin for CU unresponsive to licensed treatments. The guideline states that remibrutinib can be considered especially in patients who do not respond to both high-dose antihistamines and omalizumab, acknowledges cost restrictions on the three advanced therapies, and notes that treatments under development aim, among other approaches, to reduce mast cell numbers. A US Joint Task Force guideline that addresses the sequencing of conventional and advanced therapies was in draft for member review in 2026; the network meta-analysis commissioned for it rated standard-dose omalizumab (300 mg every 4 weeks) and remibrutinib among the most effective with high certainty. In a primary care pathway, patients who remain symptomatic and adherent after up to four times the standard antihistamine dose should be referred for specialist evaluation, where total IgE and IgG-anti-TPO may be tested to indicate the likelihood of response to omalizumab. The barzolvolimab phase 3 trials, which study adults with CSU who remain symptomatic despite H1 antihistamine treatment, enrolled 1,939 participants, including advanced therapy-experienced or refractory participants, and are designed to detect a difference in an omalizumab-refractory subpopulation. The manufacturer describes barzolvolimab as positioned “as a first-line therapy for patients with severe CSU or angioedema, and as the second-line advanced therapy of choice.” It is supplied for the trials in 1 mL pre-filled syringes for subcutaneous injection, which the manufacturer states allows potential self-administration at home.

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/); [ACAAI JTF chronic urticaria guideline announcement (2026)](https://college.acaai.org/new-chronic-urticaria-practice-parameter-update-puts-greater-emphasis-on-core-concepts-patient-centered-implementation/); [Chu et al. (2025a)](https://doi.org/10.1016/j.jaci.2025.06.004); [Ryan et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9533216/); [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and); [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm); [Celldex Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm)

<a id="topic-2.2.2.2-2"></a>

### International guideline update: development method

> “This update and revision of the international guideline for urticaria was developed in accordance with the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.2-3"></a>

### Proposed population: adults symptomatic despite H1 antihistamine treatment

> “The Phase 3 Program is designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic despite H1 antihistamine treatment.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-2.2.2.2-4"></a>

### Manufacturer positioning: first-line therapy in severe disease or angioedema and second-line advanced therapy

> “We believe barzolvolimab is well-positioned to address large CSU populations of high unmet need—as a first-line therapy for patients with severe CSU or angioedema, and as the second-line advanced therapy of choice.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-2.2.2.2-5"></a>

### Enrollment of advanced therapy-experienced participants and design for an omalizumab-refractory subpopulation

> “1,939 patients were enrolled—the largest program conducted in antihistamine refractory CSU, including patients with advanced therapy experienced/refractory CSU.”
> “The studies are designed to detect a clinically meaningful difference between each of the active arms versus placebo in the overall population as well as in the subpopulation of omalizumab refractory participants.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-2.2.2.2-6"></a>

### Care setting: subcutaneous pre-filled syringe with potential self-administration at home

> “The subcutaneous formulation allows for potential self-administration at home, eliminating the need for intravenous dosing in a hospital or clinic setting.”
> “Drug product manufacturing into 1 mL pre-filled syringes has been completed and pre-filled syringes are actively being used in Phase 3 trials.”

Source: [Celldex Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm)

<a id="topic-2.2.2.2-7"></a>

### International guideline treatment algorithm: antihistamines, then omalizumab, dupilumab, or remibrutinib, then ciclosporin

> “We recommend a 2nd generation H1-antihistamine as first-line treatment for all types of urticaria.”
> “We recommend updosing of a 2nd generation H1-antihistamine up to 4-fold in patients with chronic urticaria unresponsive to a standard-dosed 2nd generation H1-antihistamines as second-line treatment before other treatments are considered.”
> “We recommend adding on omalizumab* for the treatment of patients with CU unresponsive to high doses of 2nd generation H1-antihistamines.”
> “We suggest using dupilumab* as add-on treatment for patients with CSU unresponsive to high doses of 2nd generation H1-antihistamines.”
> “We suggest using remibrutinib* as add-on treatment for patients with CSU unresponsive to high doses of 2nd generation H1-antihistamines.”
> “We suggest using ciclosporin* for the treatment of patients with CU unresponsive to licensed treatments or if these are not available.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.2-8"></a>

### International guideline: positioning of remibrutinib and ciclosporin after omalizumab

> “The use of remibrutinib can be considered in all patients with CSU and especially in patients who do not respond to both high-dose antihistamine and omalizumab treatment.”
> “Ciclosporin is off-label for urticaria and is recommended only for patients with severe disease refractory to any other licensed treatments.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.2-9"></a>

### International guideline: cost and safety restrictions on advanced therapies

> “It is strongly recommended to stick to the treatment algorithm, but it is acknowledged that omalizumab, dupilumab, and remibrutinib have restrictions due to their high cost, and that ciclosporin restricted due to its safety profile.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.2-10"></a>

### International guideline: treatments under development that reduce mast cell numbers

> “Novel treatments currently under development aim to better regulate Type 2 immunity, or silence mast cells via inhibitory receptors, or to reduce mast cell numbers.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.2-11"></a>

### Specialist care: biomarker testing and referral for comorbidities

> “In patients under specialist care, additional tests, such as total IgE and IgG-anti-TPO may be performed, as they indicate the likelihood of response to omalizumab”
> “Therefore, any findings from the patient's medical history, physical examination, or basic testing that suggest the presence of a comorbidity or consequence of CSU should prompt further investigations.”
> “These may include screening for specific diseases by questionnaires, provocation tests, further laboratory tests, or a referral to a specialist.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.2-12"></a>

### Primary care pathway: specialist referral after up to fourfold antihistamine dosing

> “Urticaria is a common condition presenting both as acute and chronic disease within primary care.”
> “If symptoms are controlled on any dose of a long-acting non-sedating antihistamine up to a maximum of four times the standard dose or if the symptoms have spontaneously remitted, no referral is necessary.”
> “The corollary of this is that all patients who remain symptomatic and who have been adherent to medication, should be referred for specialist evaluation.”

Source: [Ryan et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9533216/)

<a id="topic-2.2.2.2-13"></a>

### Draft US joint task force guideline: member review and scope, including sequencing of advanced therapies

> “When draft clinical guidelines or practice parameters are developed by the Joint Task Force on Practice Parameters (JTFPP), ACAAI and AAAAI have the opportunity to ask members to review and comment on the drafts.”
> “The 2026 guideline focuses in greater depth on CU in children and adults, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), angioedema associated with CU, disease monitoring, comorbidities, health disparities, special populations, patient and caregiver experience, and sequencing of conventional and advanced therapies.”

Source: [ACAAI JTF chronic urticaria guideline announcement (2026)](https://college.acaai.org/new-chronic-urticaria-practice-parameter-update-puts-greater-emphasis-on-core-concepts-patient-centered-implementation/)

<a id="topic-2.2.2.2-14"></a>

### Network meta-analysis commissioned for the draft US guideline: comparative effectiveness of systemic treatments

> “As part of updating the AAAAI/ACAAI JTFPP chronic urticaria guidelines”
> “Random effects Bayesian network meta-analyses addressed urticaria activity (comprising itch and wheal scores), angioedema activity, health-related quality of life, and adverse events.”
> “This study was commissioned by the American Academy of Allergy, Asthma & Immunology and the American College of Allergy, Asthma & Immunology through the Joint Task Force on Practice Parameters for Chronic Urticaria.”
> “With high certainty, standard-dose omalizumab (300 mg every 4 weeks) and remibrutinib are among the most effective for improving multiple patient-important outcomes.”
> “The safety profile of remibrutinib, however, is less certain.”
> “Dupilumab improved urticaria activity, but its impact on quality of life is uncertain, and no dupilumab trials addressed angioedema activity.”
> “Cyclosporine may be among the most effective for improving urticaria activity but may be among the most harmful in increasing the frequency of any adverse events.”

Source: [Chu et al. (2025a)](https://doi.org/10.1016/j.jaci.2025.06.004)

Additional sources: [AAAAI/ACAAI JTF Chronic Urticaria Guideline Panel (2026)](https://college.acaai.org/wp-content/uploads/2026/06/JTF-CU_guideline-2026-06-01-For-Distribution.pdf)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
